Why Inhibikase Therapeutics, Inc.’s (IKT) Stock Is Up 5.39%
As of Tuesday, September 22, Inhibikase Therapeutics, Inc.’s IKT share price has surged by 5.39%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
Commentary & Analysis
Why Inhibikase Therapeutics, Inc.’s (IKT) Stock Is Down 5.23%
As of Tuesday, September 15, Inhibikase Therapeutics, Inc.’s IKT share price has dipped by 5.23%, which has investors questioning if this is right time to buy.Michael Rose
Why Inhibikase Therapeutics, Inc.’s (IKT) Stock Is Down 5.04%
As of Friday, July 31, Inhibikase Therapeutics, Inc.’s IKT share price has dipped by 5.04%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Inhibikase Therapeutics, Inc.’s (IKT) Stock Is Up 6.65%
As of Friday, July 24, Inhibikase Therapeutics, Inc.’s IKT share price has surged by 6.65%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Inhibikase Therapeutics, Inc.’s (IKT) Stock Is Up 9.95%
As of Tuesday, July 14, Inhibikase Therapeutics, Inc.’s IKT share price has surged by 9.95%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | IKT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $377.8 | $257.9 | 34% |
|
| Shares Out (Mil) | 174.6 | 54.3 | 74% |
|
| Institutional Ownership | 97.7% | 92.9% | 75% |
|
| Float (Mil) | 107.1 | 41.4 | 62% |
|
| Beta | 0.95 | 0.95 | 57% |
|
| Avg Daily Volume (000s) | 721 | 674 | 62% |
|
| Price Change (52-week) |
20.6% | 51.5% | 68% |
|
| Growth | IKT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | (76.7%) | (10.1%) | 3% |
|
| EPS (5yr) | 25.1% | 15.8% | 75 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (39.3%) | (15.6%) | 12% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 2 | 4 | |
| Current EPS | ($0.113) | ($0.445) | ($0.433) | |
| Month Ago EPS | ($0.113) | ($0.445) | ($0.433) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.090) | ($0.370) | ($0.380) | |
| Year/Year Chg | 0.9% | (9.4%) | (26.7%) | |
| Financials | IKT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($61) | ($43) | 15% |
|
| EPS (TTM) | ($0.433) | ($1.600) | 28% |
|
| Operating Cash Flow (TTM) (Mil) | ($43) | ($32) | 10% |
|
| Net Cash Flow (TTM) (Mil) | ($47) | $2 | 20% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $280 | $174 | 29% |
|
| Valuation | IKT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.36 | 2.51 | 58% |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | IKT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 68.9% | na |
|
| Net Margin | na | (72.5%) | na |
|
| ROA | (48.0%) | (47.7%) | 12% |
|
| ROE | (52.0%) | (54.9%) | 15% |
|
| Liabilities to Assets | 6.3% | 29.1% | 3% |
|
| F-Score | 3 | 3 | 18% |
|
Inhibikase Therapeutics, Inc. did not pass any screens on 9/25/2026.
